OptimizeRx (OPRX) announced organizational updates and leadership advancements designed to accelerate the Company’s Rule of 40 strategy-balancing sustained growth with increased profitability. Ed Stelmakh has been appointed Chief Financial & Strategic Officer; Marion Odence-Ford has been named Chief Legal & Administrative Officer; Brendan Merrell has been appointed Chief Operating Officer; Andy D’Silva has been promoted to Chief Business Officer
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Earnings Call: Strong Growth and Positive Outlook
- OptimizeRx price target raised to $20 from $14 at Citizens JMP
- OptimizeRx Reports Strong Q2 2025 Financial Growth
- OptimizeRx price target raised to $27 from $22 at Roth Capital
- OptimizeRx: Strong Q2 Performance and Upgraded Guidance Justify Buy Rating